Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Neoplasm Metastasis 2Glioma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Newly Diagnosed Glioblastoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Melanoma 1Lymphopenia 1Lymphoma, Non-Hodgkin 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 31Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Melanoma × efineptakin alfa × Clear all
NCT03901573 2025-10-22

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

NeoImmuneTech

Phase 1/2 Terminated
31 enrolled 12 charts
Dermatologic

Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡